Lumicell, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.lumicell.com
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
- Conditions
- Neoadjuvant TherapyBreast Cancer
- Interventions
- Device: Lum Imaging System
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Lumicell, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT04440982
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Palo Alto, California, United States
🇺🇸Morton Plant Mease Health Care Oncology Research, Clearwater, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Feasibility Study of LUM Imaging System for Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Lumicell, Inc.
- Registration Number
- NCT04276909
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
- Conditions
- Peritoneal Metastases
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Lumicell, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03834272
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
- Conditions
- Low Grade Glioma of BrainGlioblastomaMetastasis to Brain
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Lumicell, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03717142
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Investigation of Novel Surgical Imaging for Tumor Excision
- Conditions
- Breast Cancer
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Lumicell, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03686215
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
- Prev
- 1
- 2
- Next
News
LumiSystem Shows Promise in Reducing Radiation Need After Breast Cancer Lumpectomy
A new study presented at SABCS 2024 demonstrates that LumiSystem, combining Lumicell Direct Visualization System and pegulicianine, can help achieve broader surgical margins during lumpectomy procedures. The technology enabled 46.5% of patients to receive additional guided excisions, potentially reducing or eliminating the need for radiation therapy in select breast cancer patients.
Lumicell's Real-Time Imaging System Reduces Second Surgeries for Breast Cancer
Lumicell's technology, combining a handheld device and optical imaging agent, provides surgeons with a real-time view of cancerous tissue during lumpectomies.
Lumicell's LumiSystem Approved by FDA for Real-Time Breast Cancer Margin Assessment
The FDA has approved Lumicell's Direct Visualization System (LumiSystem) for intraoperative detection of cancerous tissue during lumpectomy surgery.